Prognostic value of a three-scale grading system based on combining molecular imaging with 68 Ga-DOTATATE and 18 F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias

• Published in: Oncotarget Vol. 11; no. 6; p. 589
• Main Authors: Karfis, Ioannis, Marin, Gwennaëlle, Levillain, Hugo, Drisis, Stylianos, Muteganya, Raoul, Critchi, Gabriela, Taraji-Schiltz, Loubna, Guix, Carlos Artigas, Shaza, Leila, Elbachiri, Meriem, Mans, Laura, Machiels, Godelieve, Hendlisz, Alain, Flamen, Patrick
• Format: Journal Article
• Language: English
• Published: United States 11.02.2020
• Subjects: 18F-FDG PET/CT; prognostic biomarkers; gastroenteropancreatic neuroendocrine neoplasias; 68Ga-DOTATATE PET/CT; molecular imaging
• ISSN: 1949-2553

We investigated on the added prognostic value of a three-scale combined molecular imaging with Ga-DOTATATE and F-FDG PET/CT, (compared to Ki-67 based histological grading), in gastroenteropancreatic neuroendocrine neoplasia patients. 85 patients with histologically proven metastatic gastroenteropancreatic neuroendocrine neoplasias, who underwent combined PET/CT imaging were retrospectively evaluated. Highest Ki-67 value available at time of F-FDG PET/CT was recorded. Patients were classified according to World Health Organization/European Neuroendocrine Tumor Society histological grades (G1, G2, G3) and into three distinct imaging categories (C1: all lesions are F-FDG negative/ Ga-DOTATATE positive, C2: patients with one or more F-FDG positive lesions, all of them Ga-DOTATATE positive, C3: patients with one or more F-FDG positive lesions, at least one of them Ga-DOTATATE negative). The primary endpoint of the study was Progression-Free Survival, assessed from the date of F-FDG PET/CT to the date of radiological progression according to Response Evaluation Criteria In Solid Tumors version 1.1. Classification according to histological grade did not show significant statistical difference in median Progression-Free Survival between G1 and G2 but was significant between G2 and G3 patients. In contrast, median Progression-Free Survival was significantly higher in C1 compared to C2 and in C2 compared to C3 patients, revealing three distinctive imaging categories, each with highly distinctive prognosis. Our three-scale combined Ga-DOTATATE/ F-FDG PET imaging classification holds high prognostic value in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias.